WebJul 16, 2024 · Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of < 6 months. The SADAL study evaluated single-agent oral selinexor in patients with RR DLBCL and demonstrated an overall response rate (ORR) of 29.1% with median duration of response (DOR) of 9.3 … WebMay 15, 2006 · Diffuse large B-cell lymphoma (DLBCL) in adults is a heterogeneous disease. Biologic subgroups of DLBCL with a favorable prognosis (germinal center B-cell-like, GCB) and with a poor prognosis (activated B-cell-like, ABC) have been defined by gene expression profiling and can be distinguished by immu …
A Combination of Acalabrutinib With R-CHOP for Patient …
WebApr 12, 2024 · Gene-expression profiling has identified subgroups of DLBCL (activated B-cell–like [ABC], germinal-center B-cell–like [GCB], and unclassified) according to cell of origin that are associated ... WebThe R-CHOP immunochemotherapy protocol has been the first-line (1L) standard of care (SOC) for diffuse large B-cell lymphoma (DLBCL) patients for decades and is curative in approximately two-thirds of patients. Numerous randomized phase III trials, most of them in an “R-CHOP ± X” design, failed to further improve outcomes. This … jemuran outin
Cancers Free Full-Text DLBCL 1L—What to Expect beyond R …
WebApr 29, 2024 · The aim of the GAINED trial is to compare obinutuzumab to rituximab when combined with an intensified chemotherapy regimen delivered every 14 days (ACVBP-14 … WebApr 2, 2024 · In 2002, the first of three trials established rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOP refers to the combination regimen) as frontline standard of care for … WebFeb 16, 2024 · Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid neoplasm, which account for 30%-40% of non-Hodgkin lymphoma (NHL) in the Western … je muri ce projet